# Retatrutide Phase 3 Monitoring System
## Track: Eli Lilly NCT05828948 | Phase 3 | Triple GLP-1/GIP/Glucagon Agonist

**Created:** 2026-04-28  
**Status:** Phase 3 Active (estimated completion: 2026-2027)  
**Purpose:** Monitor and alert when Phase 3 results become available

---

## 📊 Clinical Trials Status

| Trial ID | Phase | Status | Primary Endpoint | Est. Completion |
|----------|-------|--------|------------------|-----------------|
| **NCT05828948** | 3 | Recruiting | Weight loss % | Q4 2026 |
| NCT06153491 | 3 | Active | Liver fat (MRI-PDFF) | Q2 2027 |
| NCT06215204 | 3 | Recruiting | HbA1c reduction | Q4 2026 |

---

## 🎯 Key Endpoints to Monitor

### Primary Endpoints
```
1. Body weight reduction (% from baseline)
2. Liver fat content (MRI-PDFF)
3. HbA1c (glycemic control)
```

### Secondary Endpoints
```
- Waist circumference
- Lipid panel (TC, LDL, HDL, TG)
- Liver enzymes (ALT, AST, GGT)
- Safety (adverse events)
```

### Exploratory
```
- Muscle mass preservation (sarcopenia concern!)
- Bone density
- Cognitive function
- Cardiovascular events
```

---

## 📅 Expected Timeline

```
2026 Q2-Q3:  Topline data readout
2026 Q4:     NDA submission expected
2027 Q1:     FDA decision (PDUFA)
2027 H2:     Commercial launch (if approved)
```

---

## 🔔 Alert Triggers

| Event | Source | Alert Level |
|-------|--------|-------------|
| Phase 3 topline announced | Eli Lilly PR | 🔴 HIGH |
| Liver fat reduction >70% | Study results | 🔴 HIGH |
| Weight loss >20% | Study results | 🟡 MEDIUM |
| Safety signal (SAE) | FDA database | 🔴 HIGH |
| NDA submission | FDA website | 🟡 MEDIUM |
| FDA approval | FDA website | 🔴 RED ALERT |

---

## 📡 Data Sources

### ClinicalTrials.gov
```
URL: https://clinicaltrials.gov/trial/NCT05828948
Check: Weekly (every Monday)
Automated: Yes (cron job)
```

### Eli Lilly Pipeline
```
URL: https://www.lilly.com/pipeline
Check: Monthly
Alert: Any retatrutide update
```

### FDA Database
```
URL: https://www.accessdata.fda.gov
Check: Daily (approval updates)
```

---

## 🛠️ Monitoring Setup

### Cron Job: Weekly Check

```javascript
// arp-v24/scripts/monitor_retatrutide.js
// Runs: Every Monday 9:00 AM KST
// Alert: Telegram when update detected
```

```javascript
{
  "name": "retatrutide_phase3_monitor",
  "schedule": { "kind": "cron", "expr": "0 9 * * 1", "tz": "Asia/Seoul" },
  "payload": {
    "kind": "agentTurn",
    "message": "Check NCT05828948 status on clinicaltrials.gov. 
    If status changed, alert user. Key endpoints: weight loss %, liver fat reduction.
    Alert if: Phase 3 complete, results posted, or safety signal."
  },
  "delivery": { "mode": "announce", "channel": "telegram" }
}
```

### Check List

- [ ] NCT05828948: Recruiting → Active → Results
- [ ] NCT06153491: Liver fat endpoint study
- [ ] Lilly pipeline updates
- [ ] FDA approval status

---

## ⚠️ Safety Signals to Watch

```
🚨 Immediate Alert:
- Serious adverse events (SAE) > 5%
- Cardiac events (MACE)
- Pancreatitis cases
- Thyroid C-cell tumors (GLP-1 class warning)

⚠️ Moderate Alert:
- Muscle loss > 10% (concern for sarcopenia population)
- GI discontinuations > 15%
- Injection site reactions
```

---

## 🎯 Impact on ARP Pipeline

### If Phase 3 POSITIVE:

```
IMMEDIATE ACTIONS:
1. Elevate Retatrutide to HIGH PRIORITY
2. Update ARP v22 MASLD pipeline
3. Add to Sarcopenia combination consideration
4. Initiate partnership discussion with Eli Lilly

RATIONALE:
- 86% liver fat reduction in Phase 2 (unprecedented)
- "Best-selling drug in history" market potential
- Almost everyone is target population
```

### If Phase 3 NEGATIVE:

```
ACTIONS:
1. Monitor but don't invest
2. Focus on Resmetirom (already approved)
3. Continue Semaglutide NASH expansion
```

---

## 📊 Historical Comparison (Phase 2)

| Metric | Phase 2 Result | Historical Context |
|--------|---------------|-------------------|
| Weight loss (12mg) | **24.2%** at 48 weeks | Best in class |
| Liver fat reduction | **86%** | Unprecedented |
| Normal liver (93%) | **93%** patients | Massive effect |
| Prediabetes → Normal | **72%** | Strong metabolic |
| Curve shape | Still falling | No plateau yet |

---

## 💰 Market Opportunity

```
If approved:
- Target population: ~40% of world (obesity, MASLD, diabetes)
- Projected sales: >$50B/year (vs iPhone $230B)
- Comboly with our targets: SLC7A11 + Retatrutide?

Lilly partnership opportunity:
- Lung-specific delivery (our AAV-shYARS2)
- Combination with metabolic targets
- Clinical trial collaboration
```

---

## 🔗 Related Documents

- `ATTIA_FRAMEWORK_DRUG_ANALYSIS_2026.md` - Framework scoring
- `MASLD_DRUG_DISCOVERY_REPORT_2026.md` - NASH pipeline
- `arp-v22/` - MASLD disease pack

---

## 📝 Update Log

| Date | Event | Source |
|------|-------|--------|
| 2026-04-28 | Monitoring initiated | Current session |
| 2026-04-15 | Phase 3 active | ClinicalTrials.gov |

---

*Document: arp-v24/RETATRUTIDE_PHASE3_MONITOR_2026.md*  
*Tracking initiated: 2026-04-28*